Topics

Latest "Nielsen Norman Group" News Stories - Page: 3

12:27 EST 20th November 2019 | BioPortfolio

Here are the most relevant search results for "Nielsen Norman Group" found in our extensive news archives from over 250 global news sources.

More Information about Nielsen Norman Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Nielsen Norman Group for you to read. Along with our medical data and news we also list Nielsen Norman Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of Nielsen Norman Group Companies for you to search.

Showing "Nielsen Norman Group" News Articles 51–75 of 6,900+

Monday 18th November 2019

Unlocking the secrets of badger dispersal to minimize the spread of bovine TB

(Trinity College Dublin) By understanding how, when, and why badgers move from one social group to another, researchers hope information gleaned from GPS devices will help them tailor vaccination programs to reduce the spread of bovine tuberculosis.


New species of seaweed uncovered by genetic analyses

(Kobe University) Genetic analyses have revealed remarkably higher species diversity in common red seaweed than previously assumed. It was thought that there were only five related species of the Gloiopeltis genus worldwide. However, it has been revealed that there are over ten in Japan alone. The reinstatement of the species Gloiopeltis compressa (Ryukyu-funori) was proposed by this international...

Deep-sea bacteria copy their neighbors' diet

(Max Planck Institute for Marine Microbiology) A new group of symbiotic bacteria in deep-sea mussels surprises with the way they fix carbon: They use the Calvin cycle to turn carbon into tasty food. The bacteria acquired the genes for this process from neighboring symbiotic bacteria in the mussel. These results from a recent study by scientists from the Max Planck Institute for Marine Microbiology...


UBCO researcher examines traumatic brain injury in survivors of intimate partner violence

(University of British Columbia Okanagan campus) While the diagnoses and treatment of sport-related concussion have well-established guidelines and protocols, a new study from UBC's Okanagan campus is looking at what has previously been an understudied group -- women survivors of intimate partner violence (IPV). Their hope is to develop a simple screening tool to help front-line services, like wom...

A group of top #biotech venture capitalists are issuing a stark warning to #Congress: They won’t be able to pour money into biotech research if Democrats’ signature drug pricing bill becomes law. https://buff.ly/37gIyPF 

A group of top #biotech venture capitalists are issuing a stark warning to #Congress: They won’t be able to pour money into biotech research if Democrats’ signature drug pricing bill becomes law. https://buff.ly/37gIyPF 

Bariatric Surgery Devices Market 2019-2023 | Evolving Opportunities With Apollo Endosurgery, Inc. and Intuitive Surgical | Technavio

Technavio has been monitoring the global bariatric surgery devices market since 2014, and the market is poised to grow by USD 1.05 billion during 2019-2023 at a CAGR of close to 10% during the forecast period. Request Free Sample Pages

Arnall Golden Gregory LLP Significantly Expands its Intellectual Property and FDA Expertise as Firm Continues Strategic Growth of its Washington, D.C. Office

Group of seven new attorneys arrive with substantial patent and regulatory expertise to address legal issues related to dietary supplements and CBD Arnall Golden Gregory LLP (AGG) is pleased to announce the addition of a seven-attorney intellectual property and Food and Drug Administration (FDA) group to its Washington, D.C. office. Partners Kevin M. Bell, Richard J. Oparil, Scott A.M. Chamber...

Protalix Biotherapeutics and Chiesi Announce Successful Pre-BLA Meeting with the FDA for Accelerated Approval of their Investigational Fabry Disease Drug

CARMIEL, Israel, Nov. 18, 2019 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chiesi Farmaceutici S.p...

Replimune Group nets $75.2mm via FOPO

Replimune Group Inc. (using its Immulytic platform to develop oncolytic immuno-gene therapies) netted $75.2mm through a follo...

VA to Deploy Podimetrics SmartMat Regionally to Prevent Diabetic Foot Ulcers

– VA recently announced they will be offering a care management solution designed to detect and prevent one of the costliest and most complicated diabetes-related issues, diabetic foot ulcers, to a wider group of veterans in need.  – The solution, Podimetrics’ SmartMat, is currently in 15 VAs and starting Dec. 1, more VAs will begin ... Read More

Your NEJM Group Today: Pancytopenia & Rash Case / Chlamydia & Vaginal Microbiome / Endocrinology & Psychiatry Opportunities

Check out today's offering from NEJM Group: NEJM Primary Care/Hospitalist Page: Case record: A 66-year-old man presented to the hospital for evaluation...

Karen Hornsby Joins Advanced Dermatology and Cosmetic Surgery as Chief Managed Care Officer

Advanced Dermatology and Cosmetic Surgery (ADCS), one of the nation’s leaders in high-quality dermatology, today announced the appointment of Karen Hornsby as Chief Managed Care Officer effective November 18, 2019. Ms. Hornsby has been leading teams that built networks, negotiated contracts, improved revenue cycle management, and advised healthcare organizations for 30 years while part of org...

MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study results 18.11.2019 / 16:33 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, November 18, 2019 MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis IDMC recommends to increase patient number from currently 330 to 450.   MorphoSys (FSE: MOR; Prim...

Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis

MorphoSys AG / Key word(s): Study results Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis 18-Nov-2019 / 16:31 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc releas...

Staff shortages are affecting cancer care in Scotland, cross party group warns

Chronic staff shortages and inadequate funding are hindering efforts in Scotland to improve cancer survival rates, the Scottish parliament’s cross party group on cancer has warned. The group is made...

HealthTrust Addresses Drug Shortages by Supporting Member Access to Essential Medicines

New Contract with Fresenius Kabi HealthTrust announced today it has added two more mission-critical drugs – Diprivan® and heparin – to its proprietary pharmacy-contracting model, which is designed to help ease the impact of supply interruptions of essential medications for member hospitals. Under a new agreement with Fresenius

Biotest AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Biotest AG 18.11.2019 / 15:13 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Biotest AG Street: Landsteinerstraße 5 Postal code: 63303 City: DreieichGermany Legal Entity Iden...

A watchdog group is calling for federal action against 27 manufacturers of dietary supplements marketed as helping women become pregnant, but for which there's no evidence they're effective. https://buff.ly/2Qw7kW2 

A watchdog group is calling for federal action against 27 manufacturers of dietary supplements marketed as helping women become pregnant, but for which there's no evidence they're effective. https://buff.ly/2Qw7kW2 

#VisualAbstract: Metoprolol for the Prevention of Acute Exacerbations of COPD

1. In this double-blind randomized trial of COPD patients without previous indication for beta blocker therapy, treatment with extended-release beta-blockers failed to generate improved health outcomes versus placebo. No significant between-group difference was found in the median time until the first exacerbation of COPD. 2. Patients in the metoprolol group were more likely to experience […...

Nuvo Group presents positive data results for Remote Maternal-Fetal Heart Rate Monitoring At AHA Scientific Sessions 2019

Nuvo Group, an emerging leader in maternal-fetal health, today announced new clinical data for INVU, a pregnancy monitoring and management platform, at the American Heart Association Scientific Sessions The post Nuvo Group presents positive data results for Remote Maternal-Fetal Heart Rate Monitoring At AHA Scientific Sessions 2019 appeared first on NS Medical Devices.

Evolution Research Group and Invicro LLC Partner to Offer Clinical Research and Advanced Data Analysis and Management Services

Today, Evolution Research Group (ERG) and Invicro LLC, a Konica Minolta Company announced a strategic partnership to offer biotech and pharma sponsors early to late phase clinical research trials, advanced data analysis and project management services. ERG is a leading independent clinical research site company specializing in number of therapeutic areas including Psychiatry, Neurology, Alzheim...

Global Sarcopenia Treatment Market Size study, by Type Presarcopenia, Sarcopenia, Severe Sarcopenia, Application Hospitals, Clinics, Ambulatory Surgical Centers and Regional Forecasts 20182025 [Report Updated: 15052019] Prices from USD $3950

Global sarcopenia treatment market is valued approximately USD 2208.4 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 4.8% over the forecast period 20182025. Reduction of muscle mass considering Sarcopenia leads to loss in muscle function aligned with high changes of functional impairment, mortality and disability in the adult population. Furthermore, malnutritio...

Enigma Biomedical Group Announces Appointment of Michael Reitermann to Their Board of Directors

Enigma Biomedical Group (EBG) today announced the appointment of Michael Reitermann to their Board of Directors effective December 1, 2019. Michael Reitermann’s passion for innovation and its commercialization has driven his extensive career in the healthcare industry. After more than 20 years with Siemens Healthineers AG, he retired from the company in September 2019. Before, Michael held t...

In This World Nothing Can Be Said To Be Certain Except Death, Taxes … And Health Care Costs Going Up

The National Business Group on Health's CEO Brian Marcotte talks about the current health care landscape and where it's headed in the future. In other health industry news: the Blues team up, a hospital system settles allegations of ADA violations, and more.

Qiagen/DNA: cell high

Further gains for German diagnostics group appear limited


Quick Search

News Quicklinks